Patent Issued for Fibroblast therapy for treatment of Duchenne muscular dystrophy (USPTO 12090174).

Spinalcyte LLC has been granted a patent for fibroblast therapy to treat Duchenne muscular dystrophy. The patent highlights the importance of muscle maintenance and repair, as well as the role of inflammation and immunopathology in the disease's progression. It also acknowledges the limitations of current treatments and the need for new approaches. The patent describes a method using fibroblast cells or exosomes derived from these cells to reverse, ameliorate, or prevent symptoms associated with muscular dystrophy. The cells can be derived from various tissues and administered to the individual, resulting in improved muscle function. The patent also mentions the production of exosomes that can enhance cell proliferation. [Extracted from the article]